Founded in 2018 and headquartered in South San Francisco, California, Aligos is a clinical-stage biotechnology company that was founded with the mission to become a leader in the treatment of liver and viral diseases. As hepatologists and virologists, we focus our deep expertise on unmet medical needs where better therapies have the ability to change the lives of patients globally. Our team has successfully progressed many drugs from discovery through commercialization and we plan to continue that legacy at Aligos.

Utilizing the expertise of our medicinal chemistry and biology teams, we target liver and viral diseases with a need for better efficacy. Applying this strong scientific foundation, we have built a differentiated pipeline of best-in-class therapies.

We have purpose-built drugs with enhanced pharmacologic properties for large unmet medical needs in liver and viral diseases where better therapies will greatly impact patients.